SirPAD Subgroup Study at VIVA 2026 Focuses on Femoropopliteal PAD in Patients With Claudication
New results from the SirPAD randomized trial will be presented at VIVA 2026, October 3–6 at Bellagio Las Vegas, focusing on patients with femoropopliteal peripheral artery disease causing intermittent claudication. LAS VEGAS, Sept. 21, 2026 /PRNewswire/ -- SirPAD randomized 1,252 patients...
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- U.S. Tech Hiring Moderates as Employers Prioritize Human Skills
- Modular Data Center Market worth $93.6 billion by 2031 - Report by MarketsandMarkets™
- RMX Publishes QuantrusX Brief on Real-World Intelligence for Physical Security
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,200+ — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →